Sanofi

AstraZeneca and Sanofi's drug, Beyfortus, for preventing RSV in infants, received unanimous FDA advisory panel support. It's a single-dose, long-acting monoclonal antibody aimed at newborns and infants during their first RSV season. The panel also supported its use for children up to two years old. The drug is already approved in the U.K., EU, and Canada.

Sanofi to present new oncology data at ASCO 2023, including a first-in-human study of SAR443579, a novel NK cell engager for hematological malignancies, granted Fast Track Designation by the FDA. The company focuses on transformative therapies and strategic partnerships to address unmet medical needs in cancer treatment.

AI advancements are transforming drug discovery, with tools like AlphaFold2 enhancing protein-structure prediction. Biopharma firms are building AI capabilities through in-house expertise, acquisitions, and partnerships. Despite a decline in new AI-driven biotech companies, capital deployment has surged, with significant partnerships and some clinical trial successes. However, challenges in integration and competition persist, suggesting a future of increased M&A activity and a focus on unsaturated niches like RNA-based therapeutics.

The PAN Foundation engages in conferences and webinars to raise awareness on healthcare access, equity, and affordability, offering financial assistance for underinsured patients with chronic and rare diseases. Events include webinars on Medicare reforms, financial assistance for rare diseases, and family wellness festivals, aiming to connect patients with necessary resources.

Absci Corp. developed de novo antibodies against HER2 using zero-shot generative AI, without prior data on successful antibodies. This AI-designed antibodies, tested in a wet lab, show potential for novel cancer therapies. Absci plans to have a drug in clinical trials by 2024, marking a significant advancement in AI-driven drug discovery.

Seagen reported 2022 revenue of nearly $2 billion, a 25% increase from 2021, driven by record net product sales of $1.7 billion. The company highlighted achievements including regulatory approvals, robust development progress, and strategic partnerships. Seagen's 2023 strategy focuses on optimizing its commercial portfolio, advancing clinical development, and innovating next-generation ADC technologies. Key products like ADCETRIS, PADCEV, TUKYSA, and TIVDAK showed strong performance, with expectations for continued growth and new indications. Financial guidance for 2023 projects revenues between $2.14 billion and $2.24 billion, reflecting confidence in market expansion and product development.

The Global Type 1 Diabetes - T1D Market Report 2024 provides insights into market size, CAGR, and industry statistics, segmented by type (Rapid Acting, Long Acting, Premix Insulin Analogs) and application (Children, Adults). It covers market dynamics, trends, opportunities, and competitive landscape, including key players like Novo Nordisk and Sanofi. The report offers regional and country-level analysis, with customizable segments and data available upon request.

The article highlights Drug Hunter's selection of Molecules of the Month, focusing on compounds targeting SOS1, NLRP3, SMARCA2, and more. It discusses CNS project challenges, the E-sol metric for predicting CNS exposure, and DEL technology's role in drug discovery. Also, it mentions notable molecules like Maze’s GYS1 inhibitors and allosteric AR modulators.

The biopharmaceutical industry fears the Inflation Reduction Act's drug price negotiation could harm R&D investments. Despite concerns, major firms report increased R&D spending and optimistic future earnings. M&A activity remains strong, with a focus on small molecule drugs and treatments for older adults, showing little impact from the IRA.

The UK aims to lead in clinical research post-Brexit, focusing on regulatory reform, NHS workforce and data infrastructure, patient engagement, and innovative treatments. Emphasizing AI, digital platforms, and global trials, it seeks to accelerate drug development, improve trial efficiency, and address global health challenges.